Conformation assessment of therapeutic monoclonal antibodies by SEC-MS : Unravelling analytical biases for application to quality control
Copyright © 2020 Elsevier B.V. All rights reserved..
Immunogenicity related to the degradation of therapeutic monoclonal antibodies (mAbs) remains a major concern for their therapeutic efficacy and safety. Therefore, an analytical method allowing characterization and detection of mAbs degradation is mandatory. In this study, a simultaneous coupling of size exclusion chromatography (SEC) to native mass spectrometry (MS) and fluorescence detection (FLD) is proposed to detect degraded therapeutic mAbs and biases of structural changes (e.g. dimerization, denaturation) that may occur during native MS. A comprehensive study on infliximab behaviors have been performed under different mobile phase conditions (e.g. composition, pH, organic solvent, etc.) and MS parameters (e.g. gas temperatures, CID energies, etc.). Experimental conditions avoiding artificial denaturation and/ or dimerization have been defined. We have also demonstrated that under the developed conditions infliximab affinity towards its biological target TNFα is preserved. In addition, using this method dimers, denatured monomers and fragments could be detected in trastuzmab samples stressed by a long-term storage. These results were confirmed by using SEC coupled to ion mobility mass spectrometry as an orthogonal method for the detection of denatured monomer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
---|---|
Enthalten in: |
Journal of pharmaceutical and biomedical analysis - 185(2020) vom: 05. Juni, Seite 113252 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Le-Minh, Victor [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 26.02.2021 Date Revised 26.02.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jpba.2020.113252 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM307794563 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM307794563 | ||
003 | DE-627 | ||
005 | 20231225130336.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jpba.2020.113252 |2 doi | |
028 | 5 | 2 | |a pubmed24n1025.xml |
035 | |a (DE-627)NLM307794563 | ||
035 | |a (NLM)32193039 | ||
035 | |a (PII)S0731-7085(19)32936-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Le-Minh, Victor |e verfasserin |4 aut | |
245 | 1 | 0 | |a Conformation assessment of therapeutic monoclonal antibodies by SEC-MS |b Unravelling analytical biases for application to quality control |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.02.2021 | ||
500 | |a Date Revised 26.02.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
520 | |a Immunogenicity related to the degradation of therapeutic monoclonal antibodies (mAbs) remains a major concern for their therapeutic efficacy and safety. Therefore, an analytical method allowing characterization and detection of mAbs degradation is mandatory. In this study, a simultaneous coupling of size exclusion chromatography (SEC) to native mass spectrometry (MS) and fluorescence detection (FLD) is proposed to detect degraded therapeutic mAbs and biases of structural changes (e.g. dimerization, denaturation) that may occur during native MS. A comprehensive study on infliximab behaviors have been performed under different mobile phase conditions (e.g. composition, pH, organic solvent, etc.) and MS parameters (e.g. gas temperatures, CID energies, etc.). Experimental conditions avoiding artificial denaturation and/ or dimerization have been defined. We have also demonstrated that under the developed conditions infliximab affinity towards its biological target TNFα is preserved. In addition, using this method dimers, denatured monomers and fragments could be detected in trastuzmab samples stressed by a long-term storage. These results were confirmed by using SEC coupled to ion mobility mass spectrometry as an orthogonal method for the detection of denatured monomer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Artificial dimerization and denaturation | |
650 | 4 | |a Denatured mAb | |
650 | 4 | |a Dimer | |
650 | 4 | |a SEC-IMS-MS | |
650 | 4 | |a SEC-Native MS | |
650 | 4 | |a Therapeutic mAbs | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Infliximab |2 NLM | |
650 | 7 | |a B72HH48FLU |2 NLM | |
650 | 7 | |a Trastuzumab |2 NLM | |
650 | 7 | |a P188ANX8CK |2 NLM | |
700 | 1 | |a Halgand, Frédéric |e verfasserin |4 aut | |
700 | 1 | |a Van der Rest, Guillaume |e verfasserin |4 aut | |
700 | 1 | |a Taverna, Myriam |e verfasserin |4 aut | |
700 | 1 | |a Smadja, Claire |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical and biomedical analysis |d 1983 |g 185(2020) vom: 05. Juni, Seite 113252 |w (DE-627)NLM012641928 |x 1873-264X |7 nnns |
773 | 1 | 8 | |g volume:185 |g year:2020 |g day:05 |g month:06 |g pages:113252 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpba.2020.113252 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 185 |j 2020 |b 05 |c 06 |h 113252 |